Methods and Compositions for Inhibiting GSK-3 In Glial Cell Related Disorders

• US 20100143500A1
• Filed: 10/31/2007
• Published: 06/10/2010
• Est. Priority Date: 10/31/2006
• Status: Abandoned Application

• Current Assignee: Ohio State University
• Original Assignee: The Ohio State University Research Foundation
• Inventors: Chiocca, E. Antonio, Nowicki, Michal Oskar, Lawler, Sean E.
• Application Number:
  US12/447,811
• Publication Number:
  US 20100143500A1
• Time in Patent Office: Days
• US Class Current: 424/677
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4015 having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• CPC Class Codes: A61K 31/426 1,3-Thiazoles
• CPC Class Codes: A61K 33/14 Alkali metal chlorides; Alkaline earth metal chlorides
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12Q 1/485 involving kinase
• CPC Class Codes: G01N 2333/912 transferring phosphorus containing groups, e.g. kinases (2.7)
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 33/57407 Specifically defined cancers

Abstract

A method of treating a glial cell related disorder in a mammalian subject includes administering a drug which enhances or prolongs GSK-3 α or β inactivation.

Claims

1. A method of treating a glial cell related disorder in a mammalian subject comprising administering a drug to the subject, wherein the drug enhances or prolongs GSK-3 α

or β

inactivation.

2. The method of claim 1, wherein the drug can block glial cell invasion or inhibit glial cell migration.

3. The method of claim 1, wherein the glial cell related disorder comprises one or more gliomas.

4. The method of claim 1, wherein the glial cell related disorder leads to glioma spheroid expansion.

5. The method of claim 1, wherein the subject is in need or regenerating nerve cells.

6. The method of claim 1, wherein the drug comprises one or more of:

LiCl, SB415286 and AR-A-14418.

7. The method of claim 1, wherein the glial cell related disorder is characterized by misregulation of GSK-3.

8. The method of claim 1, wherein the glial cell related disorder comprises inhibiting recurrence of a glioma tumor.

10. The method of claim 1 useful as a therapeutic tool to prevent recurrence or further tumor spread.

9. A method for screening or identifying a compound useful in treating glial cell related disorders, comprising identifying inhibitory and stimulatory compounds capable of enhancing or prolonging GSK-3 α

or β

inactivation.

11. A medicament for treating a glial cell related disorder in a mammalian subject comprising administering a drug to the subject, wherein the medicament comprises a drug which drug enhances or prolongs GSK-3 α

or β

inactivation.

12. The medicament of claim 11, wherein the drug can block glial cell invasion or inhibit glial cell migration.

13. The medicament of claim 11, wherein, wherein the glial cell related disorder comprises one or more gliomas.

14. The medicament of claim 11, wherein, wherein the glial cell related disorder leads to glioma spheroid expansion.

15. The medicament of claim 11, wherein, wherein the subject is in need or regenerating nerve cells.

16. The medicament of claim 11, wherein, wherein the drug comprises one or more of:

LiCl, SB415286 and AR-A-14418.

17. The medicament of claim 11, wherein, wherein the glial cell related disorder is characterized by misregulation of GSK-3.

18. The medicament of claim 11, wherein, wherein the glial cell related disorder comprises inhibiting recurrence of a glioma tumor.

19. A biomarker for glioma cell invasion or migration comprising glycogen synthase kinase-3 (GSK-3).

20. A method for evaluating invasion or migration of glial cells comprising using glycogen synthase kinase-3 (GSK-3) as a biomarker therefor.